Mr. Smith has served in senior executive positions with a number of public and private biotechnology and pharmaceutical companies, all of which have been involved in the discovery and development of new drugs, in multiple therapeutic areas.  He has been Chief Executive Officer and a director of Virolab, Inc., President, Chief Executive Officer and Director for Genelabs Technologies, Inc. (Nasdaq:GNLB) and Executive Director of Worldwide Business Development at ICN Pharmaceuticals, Inc. (NYSE:ICN), now known as Valeant Pharmaceuticals International.